Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
53 hedge funds and large institutions have $7.91M invested in Repros Therapeutics Inc. in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 20 reducing their positions, and 9 closing their positions.
188% more call options, than puts
Call options by funds: $207K | Put options by funds: $72K
5% less funds holding
Funds holding: 56 → 53 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
35% less capital invested
Capital invested by funds: $12.3M → $7.91M (-$4.34M)
65% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$316K |
| 2 |
GCM
Gruss Capital Management
New York
|
+$289K |
| 3 |
Renaissance Technologies
New York
|
+$140K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$27.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.32M |
| 2 |
Millennium Management
New York
|
-$318K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$220K |
| 4 |
RA
Royce & Associates
New York
|
-$156K |
| 5 |
Goldman Sachs
New York
|
-$112K |
RPRX Hedge Fund Activity: Q1 2016 in Review
53 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q1 2016, worth a combined $7.91M — down 35% from $12.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RPRX and 6 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 7 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $316K. The largest seller was Fidelity Investments, cutting an estimated $1.32M.
- 53 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q1 2016, down from 56 in Q4 2015.
- Funds reported $7.91M of Repros Therapeutics Inc. stock for Q1 2016, down 35% quarter-over-quarter.
- 6 funds opened new Repros Therapeutics Inc. positions in Q1 2016 and 9 closed out, a net change of -3 holders.
- The largest Repros Therapeutics Inc. buyer in Q1 2016 was Jacobs Levy Equity Management, an estimated $316K added.
- The largest Repros Therapeutics Inc. seller in Q1 2016 was Fidelity Investments, an estimated $1.32M sold.
Based on aggregated 13F filings for Q1 2016.